$GOVX

GeoVax Labs, Inc.

GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and solid tumor cancers. Its main programs include GEO-MVA, a vaccine candidate for mpox, smallpox and other poxviruses; Gedeptin, a gene-directed therapy for solid tumors, including head and neck cancers; and GEO-CM04S1, a multi-antigen COVID-19 vaccine being evaluated in clinical trials. GeoVax also develops preclinical vaccines for Ebola, Sudan and Marburg viruses using its GV-MVA-VLP platform. GeoVax aims to advance its candidates through clinical development and pursue approval and commercialization through internal development, licensing and partnerships. It relies primarily on third-party contract manufacturers to produce clinical trial materials and has not commercialized products. GeoVax is headquartered in Smyrna, Georgia.

No enriched coverage for $GOVX in the last 7 days.

No SEC Form 4 filings for $GOVX in the last 30 days.

See all $GOVX insider activity →

GeoVax Labs, Inc. (GOVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Director Effective November 5, 2026, the Board of Directors appointed Shahin Behroyan as a director of the Co

GOVX sentiment & insider activity

Recent GOVX coverage spans corporate actions and earnings.

What's driving GOVX

AlphAI scores every news story that mentions GOVX with an AI model for sentiment and relevance, and aggregates insider trades from GeoVax Labs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GOVX

Score
$GOVXLowExec change· appointed

GeoVax Labs, Inc. (GOVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Director Effective November 5, 2026, the Board of Directors appointed Shahin Behroyan as a director of the Co

GeoVax Labs terminates CEO David A. Dodd, who remains board chairman

GeoVax Labs terminated CEO David A. Dodd for non-compliance with board directives, effective immediately. Dodd remains a board director and chairman. The company stated the termination was for cause, but this has not been legally determined. GeoVax will not pay severance or vest options unless the cause determination is overturned, which could entitle Dodd to compensation. According to the company, the decision was disclosed in an SEC filing.

$GOVXMedExec change· terminated

GeoVax Labs, Inc. (GOVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) Termination of President and Chief Executive Officer On November 5, 2026, David A. Dodd was terminated as President and

$GOVXLowShareholder vote

GeoVax Labs, Inc. (GOVX): Submission of Matters to a Vote of Security Holders

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held a special meeting of stockholders on October 27, 2026. The Company received proxies totaling 4,326,013 of its 9,093,871 issued and outstanding shares of common stock as of the record date of August 28

$GOVXLowDebt financing· $1M

GeoVax Labs, Inc. (GOVX): Entry into a Material Definitive Agreement

GeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 GeoVax Enters into $1 Million Revolving Loan Agreement ATLANTA, GA – October 26, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that it has en

Related tickers